ABCELLERA BIOLOGICS INC (ABCL) Fundamental Analysis & Valuation

NASDAQ:ABCL • CA00288U1066

Current stock price

3.825 USD
+0.07 (+1.73%)
Last:

This ABCL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ABCL Profitability Analysis

1.1 Basic Checks

  • In the past year ABCL has reported negative net income.
  • ABCL had a negative operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: ABCL reported negative net income in multiple years.
  • The reported operating cash flow has been mixed in the past 5 years: ABCL reported negative operating cash flow in multiple years.
ABCL Yearly Net Income VS EBIT VS OCF VS FCFABCL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M -200M -300M

1.2 Ratios

  • ABCL has a Return On Assets (-10.79%) which is comparable to the rest of the industry.
  • Looking at the Return On Equity, with a value of -15.14%, ABCL is in line with its industry, outperforming 54.39% of the companies in the same industry.
Industry RankSector Rank
ROA -10.79%
ROE -15.14%
ROIC N/A
ROA(3y)-10.87%
ROA(5y)-2.13%
ROE(3y)-14.42%
ROE(5y)-3.09%
ROIC(3y)N/A
ROIC(5y)N/A
ABCL Yearly ROA, ROE, ROICABCL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 -20

1.3 Margins

  • ABCL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABCL Yearly Profit, Operating, Gross MarginsABCL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. ABCL Health Analysis

2.1 Basic Checks

  • ABCL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ABCL has been increased compared to 1 year ago.
  • The number of shares outstanding for ABCL has been increased compared to 5 years ago.
  • There is no outstanding debt for ABCL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ABCL Yearly Shares OutstandingABCL Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
ABCL Yearly Total Debt VS Total AssetsABCL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • ABCL has an Altman-Z score of 1.84. This is not the best score and indicates that ABCL is in the grey zone with still only limited risk for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 1.84, ABCL is in line with its industry, outperforming 52.63% of the companies in the same industry.
  • There is no outstanding debt for ABCL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.84
ROIC/WACCN/A
WACC9.83%
ABCL Yearly LT Debt VS Equity VS FCFABCL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B

2.3 Liquidity

  • ABCL has a Current Ratio of 11.32. This indicates that ABCL is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 11.32, ABCL belongs to the top of the industry, outperforming 96.49% of the companies in the same industry.
  • A Quick Ratio of 11.23 indicates that ABCL has no problem at all paying its short term obligations.
  • ABCL has a better Quick ratio (11.23) than 96.49% of its industry peers.
Industry RankSector Rank
Current Ratio 11.32
Quick Ratio 11.23
ABCL Yearly Current Assets VS Current LiabilitesABCL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. ABCL Growth Analysis

3.1 Past

  • ABCL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.91%, which is quite good.
  • The Revenue has grown by 160.55% in the past year. This is a very strong growth!
  • The Revenue for ABCL have been decreasing by -20.27% on average. This is quite bad
EPS 1Y (TTM)10.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.73%
Revenue 1Y (TTM)160.55%
Revenue growth 3Y-46.31%
Revenue growth 5Y-20.27%
Sales Q2Q%788.18%

3.2 Future

  • The Earnings Per Share is expected to decrease by -4.55% on average over the next years.
  • Based on estimates for the next years, ABCL will show a very strong growth in Revenue. The Revenue will grow by 26.95% on average per year.
EPS Next Y-57.86%
EPS Next 2Y-29.21%
EPS Next 3Y-18.9%
EPS Next 5Y-4.55%
Revenue Next Year-16.2%
Revenue Next 2Y1.92%
Revenue Next 3Y1.15%
Revenue Next 5Y26.95%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ABCL Yearly Revenue VS EstimatesABCL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M
ABCL Yearly EPS VS EstimatesABCL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 0.5 -0.5 1 1.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. ABCL Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ABCL. In the last year negative earnings were reported.
  • Also next year ABCL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABCL Price Earnings VS Forward Price EarningsABCL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABCL Per share dataABCL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

  • ABCL's earnings are expected to decrease with -18.90% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-29.21%
EPS Next 3Y-18.9%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ABCL Dividend Analysis

5.1 Amount

  • ABCL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ABCL Fundamentals: All Metrics, Ratios and Statistics

ABCELLERA BIOLOGICS INC

NASDAQ:ABCL (4/15/2026, 1:41:48 PM)

3.825

+0.07 (+1.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-24
Earnings (Next)05-10
Inst Owners37.27%
Inst Owner Change0.01%
Ins Owners4.25%
Ins Owner Change0.14%
Market Cap1.16B
Revenue(TTM)75.13M
Net Income(TTM)-146.41M
Analysts81.43
Price Target9.35 (144.44%)
Short Float %21.54%
Short Ratio14.62
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)36.36%
Min EPS beat(2)-10.38%
Max EPS beat(2)83.1%
EPS beat(4)2
Avg EPS beat(4)24.57%
Min EPS beat(4)-10.38%
Max EPS beat(4)83.1%
EPS beat(8)5
Avg EPS beat(8)18.35%
EPS beat(12)7
Avg EPS beat(12)13.64%
EPS beat(16)9
Avg EPS beat(16)-94.95%
Revenue beat(2)2
Avg Revenue beat(2)336.89%
Min Revenue beat(2)48.58%
Max Revenue beat(2)625.19%
Revenue beat(4)3
Avg Revenue beat(4)200.66%
Min Revenue beat(4)-44.84%
Max Revenue beat(4)625.19%
Revenue beat(8)3
Avg Revenue beat(8)88.62%
Revenue beat(12)4
Avg Revenue beat(12)53.61%
Revenue beat(16)6
Avg Revenue beat(16)40.17%
PT rev (1m)-6.78%
PT rev (3m)-6.78%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-13.43%
EPS NY rev (1m)0%
EPS NY rev (3m)-8.08%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-29.58%
Revenue NY rev (1m)-3.77%
Revenue NY rev (3m)-23.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 15.44
P/FCF N/A
P/OCF N/A
P/B 1.2
P/tB 1.32
EV/EBITDA N/A
EPS(TTM)-0.49
EYN/A
EPS(NY)-0.77
Fwd EYN/A
FCF(TTM)-0.57
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS0.25
BVpS3.19
TBVpS2.91
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -10.79%
ROE -15.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-10.87%
ROA(5y)-2.13%
ROE(3y)-14.42%
ROE(5y)-3.09%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 192.92%
Cap/Sales 56.93%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.32
Quick Ratio 11.23
Altman-Z 1.84
F-Score6
WACC9.83%
ROIC/WACCN/A
Cap/Depr(3y)198.98%
Cap/Depr(5y)252.19%
Cap/Sales(3y)177.55%
Cap/Sales(5y)112.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.73%
EPS Next Y-57.86%
EPS Next 2Y-29.21%
EPS Next 3Y-18.9%
EPS Next 5Y-4.55%
Revenue 1Y (TTM)160.55%
Revenue growth 3Y-46.31%
Revenue growth 5Y-20.27%
Sales Q2Q%788.18%
Revenue Next Year-16.2%
Revenue Next 2Y1.92%
Revenue Next 3Y1.15%
Revenue Next 5Y26.95%
EBIT growth 1Y31.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year6.33%
EBIT Next 3Y4.22%
EBIT Next 5Y2.56%
FCF growth 1Y6.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-20.95%
OCF growth 3YN/A
OCF growth 5YN/A

ABCELLERA BIOLOGICS INC / ABCL Fundamental Analysis FAQ

What is the ChartMill fundamental rating of ABCELLERA BIOLOGICS INC (ABCL) stock?

ChartMill assigns a fundamental rating of 3 / 10 to ABCL.


What is the valuation status for ABCL stock?

ChartMill assigns a valuation rating of 0 / 10 to ABCELLERA BIOLOGICS INC (ABCL). This can be considered as Overvalued.


What is the profitability of ABCL stock?

ABCELLERA BIOLOGICS INC (ABCL) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for ABCL stock?

The Earnings per Share (EPS) of ABCELLERA BIOLOGICS INC (ABCL) is expected to decline by -57.86% in the next year.